Bellevue Asset Management »

Eli Lilly & Co. shares owned by Bellevue Asset Management

Quarter-by-quarter ownership of Eli Lilly & Co. (LLY) shares owned by Bellevue Asset Management from 13F filings

Historical chart of Bellevue Asset Management investment in Eli Lilly & Co.

Tip: Access up to 7 years of quarterly data

All positions including Eli Lilly & Co. held by Bellevue Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Eli Lilly & Co. by Bellevue Asset Management

Quarter filed Position value Share count Share price at filing
2015-12-31 $2.9M 35k 84.26
2015-09-30 $2.9M 35k 83.69
2015-06-30 $1.7M 20k 83.50

More positions owned by Bellevue Asset Management

Celgene Corporation
Biogen Idec (BIIB)
Gilead Sciences (GILD)
Amgen (AMGN)
Regeneron Pharmaceuticals (REGN)
Medtronic
Illumina (ILMN)
Abbott Laboratories (ABT)
Mylan
Becton, Dickinson and (BDX)
Cardinal Health (CAH)
UnitedHealth (UNH)
Stryker Corporation (SYK)
Teva Pharmaceutical Industries (TEVA)
Express Scripts Holding

View all positions for Bellevue Asset Management

Top funds holding Eli Lilly & Co.

Lilly Endowment
Vanguard Group
BlackRock
Pnc Financial Services
FMR
PRIMECAP Management Company
T. Rowe Price Associates
Jpmorgan Chase & Co
Geode Capital Management
Morgan Stanley
State Farm Mutual Automobile Insurance Company
Wellington Management Company
Bank of America Corporation
Northern Trust
Jennison Associates

View all funds holding Eli Lilly & Co.